Clinical experience of MEK inhibitors in cancer therapy

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1773, Issue 8, 2007, Pages 1248-1255

  Wang, Ding ^a   Boerner, Scott A ^a   Winkler, James D ^b   LoRusso, Patricia M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARRAY BIOPHARMA INC   (United States)

Author keywords

MAPK; MEK; Targeted therapy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ARRY 142886; AZD 6244; B RAF KINASE; BCR ABL PROTEIN; BENZIMIDAZOLE DERIVATIVE; COMPLEMENTARY DNA; KI 67 ANTIGEN; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; MUTANT PROTEIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ASTHENIA; BLURRED VISION; CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG RESEARCH; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; ENZYME INHIBITION; FACE EDEMA; FATIGUE; GENE MUTATION; HALLUCINATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; TASTE; VISUAL DISORDER; VOMITING;

CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 34547482919     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2006.11.009     Document Type: Review

References (46)

1. Mansour S.J., Matten W.T., Hermann A.S., Candia J.M., Rong S., Fukasawa K., Vande Woude G.F., and Ahn N.G. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265 (1994) 966-970
2. Seger R., Ahn N.G., Posada J., Munar E.S., Jensen A.M., Cooper J.A., Cobb M.H., and Krebs E.G. Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J. Biol. Chem. 267 (1992) 14373-14381
3. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-i S., Wada H., Fujimoto J., and Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18 (1999) 813-822
4. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev., Cancer 3 (2003) 11-22
5. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 49 (1989) 4682-4689
6. Shields J.M., Pruitt K., McFall A., Shaub A., and Der C.J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10 (2000) 147-154
7. Seabra M.C. Membrane association and targeting of prenylated Ras-like GTPases. Cell. Signal. 10 (1998) 167-172
8. Van Cutsem E., Karasek P., Oettle H., Vervenne W.L., Szawlowski A., Schoffski P., Post S., Neumann H., Safran H., Humblet Y., van de Velde H., Ma Y., and Von Hoff D. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc.-Am. Soc. Clin. Oncol. 21 (2002) (abstr 517) 130a
9. Singer G., Oldt III R., Cohen Y., Wang B.G., Sidransky D., Kurman R.J., and Shih Ie M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95 (2003) 484-486
10. Xu X., Quiros R.M., Gattuso P., Ain K.B., and Prinz R.A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63 (2003) 4561-4567
11. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., Carson K.A., Vasko V., Larin A., Tallini G., Tolaney S., Holt E.H., Hui P., Umbricht C.B., Basaria S., Ewertz M., Tufaro A.P., Califano J.A., Ringel M.D., Zeiger M.A., Sidransky D., and Ladenson P.W. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90 (2005) 6373-6379
12. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., and Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63 (2003) 1454-1457
13. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
14. Lee J.T., and McCubrey J.A. BAY-43-9006 Bayer/Onyx. Curr. Opin. Investig. Drugs 4 (2003) 757-763
15. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., and Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362
16. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., Copeland R.A., Magolda R.L., Scherle P.A., and Trzaskos J.M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273 (1998) 18623-18632
17. Dudley D.T., Pang L., Decker S.J., Bridges A.J., and Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7686-7689
18. Sebolt-Leopold J.S., Dudley D.T., Herrera R., Van Becelaere K., Wiland A., Gowan R.C., Tecle H., Barrett S.D., Bridges A., Przybranowski S., Leopold W.R., and Saltiel A.R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5 (1999) 810-816
19. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev., Cancer 4 (2004) 937-947
20. Wallace E., Yeh T., Lyssikatos J., Winkler J., Lee P., Marlow A., Hurley B., Marsh V., Bernat B., Evans R., Colwell H., Ballard J., Morales T., Smith D., Brandhuber B., Gross S., Poch G., Litwiler K., Hingorani G., Otten J., Sullivan F., Blake J., Pheneger T., Goyette M., and Koch K. Preclinical development of ARRY-142886, a potent and selective MEK inhibitor. Proc. Am. Assoc. Cancer Res. 45 (2004) (abs 3891) 897
21. Xing C., and Imagawa W. Altered MAP kinase (ERK1,2) regulation in primary cultures of mammary tumor cells: elevated basal activity and sustained response to EGF. Carcinogenesis 20 (1999) 1201-1208
22. Murphy L.O., Cluck M.W., Lovas S., Otvos F., Murphy R.F., Schally A.V., Permert J., Larsson J., Knezetic J.A., and Adrian T.E. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br. J. Cancer 84 (2001) 926-935
23. Boucher M.J., Morisset J., Vachon P.H., Reed J.C., Laine J., and Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem. 79 (2000) 355-369
24. Meng X.W., Chandra J., Loegering D., Van Becelaere K., Kottke T.J., Gore S.D., Karp J.E., Sebolt-Leopold J., and Kaufmann S.H. Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J. Biol. Chem. 278 (2003) 47326-47339
25. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., and Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270 (1995) 27489-27494
26. Duncia J.V., Santella III J.B., Higley C.A., Pitts W.J., Wityak J., Frietze W.E., Rankin F.W., Sun J.H., Earl R.A., Tabaka A.C., Teleha C.A., Blom K.F., Favata M.F., Manos E.J., Daulerio A.J., Stradley D.A., Horiuchi K., Copeland R.A., Scherle P.A., Trzaskos J.M., Magolda R.L., Trainor G.L., Wexler R.R., Hobbs F.W., and Olson R.E. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg. Med. Chem. Lett. 8 (1998) 2839-2844
27. Wang Z., Li Y., Liu E.T., and Yu Q. Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. Biochem. Biophys. Res. Commun. 322 (2004) 609-613
28. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
29. Duan W., Chan J.H., Wong C.H., Leung B.P., and Wong W.S. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J. Immunol. 172 (2004) 7053-7059
30. Lorusso P.M., Adjei A.A., Varterasian M., Gadgeel S., Reid J., Mitchell D.Y., Hanson L., DeLuca P., Bruzek L., Piens J., Asbury P., Van Becelaere K., Herrera R., Sebolt-Leopold J., and Meyer M.B. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 23 (2005) 5281-5293
31. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., Hamid O., Varterasian M., Asbury P., Kaldjian E.P., Gulyas S., Mitchell D.Y., Herrera R., Sebolt-Leopold J.S., and Meyer M.B. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22 (2004) 4456-4462
32. Lorusso P., Krishnamurthi S., Rinehart J.R., Nabell L., Croghan G., Varterasian M., Sadis S.S., Menon S.S., Leopold J., and Meyer M.B. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J. Clin. Oncol. (Meet. Abstr.) 23 (2005) 3011
33. Menon S.S., Whitfield L.R., Sadis S., Meyer M.B., Leopold J., Lorusso P.M., Krishnamurthi S., Rinehart J.R., Nabell L., and Croghan G. Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. J. Clin. Oncol. (Meet. Abstr.) 23 (2005) 3066
34. Lyssikatos J., Yeh T., Wallace E., Marsh V., Bernat B., Gross S., Evans R., Colwell H., Parry J., Baker S., Ballard J., Morales T., Smith D., Brandhuber B., and Winkler J. ARRY-142886, a potent and selective MEK inhibitor: I) ATP-independent inhibition results in high enzymatic and cellular selectivity. Proc. Am. Assoc. Cancer Res. 45 (2004) abs 3888
35. T.C. Yeh, V. Marsh, B.A. Bernat, J. Ballard, H. Colwell, R.J. Evans, J. Parry, D. Smith, B.J. Brandhuber, S. Gross, A. Marlow, B. Hurley, J. Lyssikatos, P.A. Lee, J.D. Winkler, K. Koch, E. Wallace, Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly-selective MEK 1/2 Inhibitor. (in press).
36. Yeh T., Wallace E., Lyssikatos J., and Winkler J. ARRY-142886, a potent and selective MEK inhibitor: II) Potency against cellular MEK leads to inhibition of cellular proliferation and induction of apoptosis in cell lines with mutant Ras or B-Raf. Proc. Am. Assoc. Cancer Res. 45 (2004) abs 3889
37. Lee P., Wallace E., Yeh T., Poch G., Litwiler K., Pheneger T., Lyssikatos J., and Winkler J. ARRY-142886, a potent and selective MEK inhibitor: III) Efficacy in murine xenograft models correlates with decreased ERK phosphorylation. Proc. Am. Assoc. Cancer Res. 45 (2004) abs 3890
38. Chow L.Q.M., Eckhardt S.G., Reid J.M., Molina J., Hanson L., Piens J., Hariharan S., Basche M., Gore L., Diab S., O'Bryant C., Grolnic S., Hippert B., Doyle M.P., Maloney L., Gordon G., Brown S., Litwiler K., Poch G., and Adjei A.A. A First in Human Dose-Ranging Study to Assess the Pharmacokinetics, Pharmacodynamics, and Toxicities of the MEK Inhibitor, ARRY-142886 (AZD6244) in Patients with Advanced Solid Malignancies, International Conference on Molecular Targets and Cancer Therapeutics, EORTC, November, 2005 (2005)
39. Adjei A.A., Cohen R.B., Franklin W.A., Molina J., Hariharan S., Temmer E., Brown S., Maloney L., Morris C., and Eckhardt S.G. Phase I Pharmacokinetic and Pharmacodynamic Study of the MEK Inhibitor AZD6244 (ARRY-142886), International Conference on Molecular Targets and Cancer Therapeutics, EORTC, November, 2006 (2006)
40. Ohren J.F., Chen H., Pavlovsky A., Whitehead C., Zhang E., Kuffa P., Yan C., McConnell P., Spessard C., Banotai C., Mueller W.T., Delaney A., Omer C., Sebolt-Leopold J., Dudley D.T., Leung I.K., Flamme C., Warmus J., Kaufman M., Barrett S., Tecle H., and Hasemann C.A. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11 (2004) 1192-1197
41. McCubrey J.A., Steelman L.S., Abrams S.L., Lee J.T., Chang F., Bertrand F.E., Navolanic P.M., Terrian D.M., Franklin R.A., D'Assoro A.B., Salisbury J.L., Mazzarino M.C., Stivala F., and Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46 (2006) 249-279
42. Smalley K.S., Haass N.K., Brafford P.A., Lioni M., Flaherty K.T., and Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5 (2006) 1136-1144
43. Hofmann W.K., Komor M., Hoelzer D., and Ottmann O.G. Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk. Lymphoma 45 (2004) 655-660
44. Haber D.A., Bell D.W., Sordella R., Kwak E.L., Godin-Heymann N., Sharma S.V., Lynch T.J., and Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harbor Symp. Quant. Biol. 70 (2005) 419-426
45. Delaney A.M., Printen J.A., Chen H., Fauman E.B., and Dudley D.T. Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol. Cell. Biol. 22 (2002) 7593-7602
46. Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., Cruz M.S., McCormick F., and Rauen K.A. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311 (2006) 1287-1290